Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone

References

• Gatter K C, Warnke R A. Diffuse large B-cell lymphoma. World Health Organization Classification of Tumours: Tumours of Hematopoietic and Lymphoid Tissues, E S Jaffe, N L Harriw, H Stein, J W Vardiman. IARC Press, Lyon 2001; 171–174
   Google Scholar
• Habermann T M, Weller E A, Morrison V A, Gascoyne R D, Cassileth P A, Cohn J B, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma [see comments]. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Chen C I, Roitman D, Tsang R, Stewart A K, Keating A, Crump M. ‘Relative’ chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 30: 885–891
   PubMed Web of Science ®Google Scholar
• Josting A, Sieniawski M, Glossmann J P, Staak O, Nogova L, Peters N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005; 16: 1359–1365
   PubMed Web of Science ®Google Scholar
• Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004; 72: 10–17
   PubMed Web of Science ®Google Scholar
• Mey U J, Olivieri A, Orlopp K S, Rabe C, Strehl J W, Gorschlueter M, et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma 2006; 47: 2558–2566
   PubMed Web of Science ®Google Scholar
• Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• McMaster M L, Greer J P, Greco F A, Johnson D H, Wolff S N, Hainsworth J D. Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol 1991; 9: 941–946
   PubMed Web of Science ®Google Scholar
• Ardeshna K M, Kakouros N, Qian W, Powell M G, Saini N, D'Sa S, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol 2005; 130: 363–372
   PubMed Web of Science ®Google Scholar
• Velasquez W S, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Moskowitz C, Bertino J, Glassman J, Hedrick E, Hunte S, Coady-Lyons N, et al. Ifosphamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785
   PubMed Web of Science ®Google Scholar
• Hanel M, Kroger N, Kroschinsky F, Birkmann J, Hanel A, Herbst R, et al. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma. J Cancer Res Clin Oncol 2001; 127: 387–395
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Chabner B A, Pearson D, Steinberg S M, Jaffe E S, Cheson B D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18: 3633–3642
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Nimer S D, Portlock C, Straus D, Noy A, et al. Rituximab and ICE (RICE) as second-line therapy prior to autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688
   PubMed Web of Science ®Google Scholar
• Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005; 92: 1352–1357
   PubMed Web of Science ®Google Scholar
• Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006; 17(Suppl 4)iv31–iv32
   PubMed Web of Science ®Google Scholar